You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
药明生物(02269.HK)逆市续跌逾2%失牛熊线遭母企减持套逾38亿元股份上板
阿思达克 06-19 12:36

遭母企折让5%减持股份套现逾38亿元的药明生物(02269.HK)市前有四宗各1,380万股(合共5,520万股)以每股69.3元非自动对盘上板,该股今天逆市失守250天线(71.7元),最多续跌3.7%低见70.25元,半日收71.45元,续跌逾2%,半日成交增至6,639万股,涉资46.21亿元。

药明生物公布,控股股东Wuxi Biologics以每股69.3元(较昨天收市价折让5%),减持公司5,500万股,套现38.12亿元,完成後,其持有量由50.42%减至约45.98%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account